Investor Presentation

November 04, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block - G Dalal Street Bandra-Kurla Complex Mumbai – 400001 Bandra (East), Mumbai - 400051 Scrip Code: 524404 Symbol: MARKSANS Sub: Investor Presentation Dear Sir/Madam, Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith the investor presentation for Q2FY27. We request you to take the aforesaid on record. Thanking you. Yours faithfully For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Enclosed as above Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com Earnings Presentation Q2 & H1 FY27 4th November 2026 BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026 ©2026 – Marksans Pharma Ltd., All Rights Reserved www.marksanspharma.com Safe Harbor This presentation has been prepared by Marksans Pharma Limited (the “Company”) solely for informational purposes. The information contained herein is not intended to be comprehensive and should not be relied upon as the sole basis for any investment or business decision. This presentation may contain forward-looking statements, including, but not limited to, statements regarding the Company’s business strategies, operations, financial condition, and future performance. These forward-looking statements are based on current expectations, assumptions, and estimates, and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. www.marksanspharma.com Page 2 Q2 H1FY27 Financial Business Highlights Q2 & H1FY27 Financial & Business 01 04 Highlights 02 Q2FY27 Geographical Highlights 11 Marksans Pharma at a Glance 03 Marksans Pharma at a Glance 18 Table of Marksans’ Journey 04 Marksans’ Journey 25 Contents Strategic Initiatives 05 Strategic Initiatives 31 Sustainability at Marksans 06 Sustainability at Marksans 40 Annexure 07 Annexure 48 www.marksanspharma.com Page 3 Q2 & H1FY27 Financial & Business Highlights www.marksanspharma.com Page 4 Management Commentary “Q2FY27 marks a landmark quarter for Marksans Pharma, with the Company delivering its strongest-ever performance. Revenue reached ₹940 crore, up 30.5% YoY. Adjusted for acquisition (QliniQ) impact, revenue growth remained healthy Mark Saldanha at 25%. EBITDA grew 48.3% to a record ₹214 crore, with margins expanding 274 bps to 22.8%. For H1FY27, revenue grew 32.9% FOUNDER, CHAIRMAN & MANAGING DIRECTOR to ₹1,781 crore, EBITDA rose 74.7% with margins up 574 bps to 24.0%, and PAT nearly doubled to ₹303 crore, already over 70% of our full-year FY26 profit. Growth was broad-based. UK & Europe grew 64.9% to a record ₹405 crore in Q2, with the base business growing 48.6% organically and QliniQ, our new European front-end, contributing around ₹84 crore in H1. Australia & New Zealand grew 64.0%, and US & North America delivered its highest-ever quarter at ₹421 crore. Equally encouraging was the strength of cash generation, with H1 operating cash flow reaching ₹322 crore, 4.3 times the previous year, and cash balances closing at ₹1,124 crore. Our trailing twelve-month ROCE also improved to 24.7%. We enter the next phase of our growth journey from a position of considerable strength, supported by an expanding global footprint, a robust product pipeline and a strong net-cash position. Our focus remains on sustaining profitable organic growth while selectively pursuing strategic acquisitions that strengthen our capabilities and market presence. We remain confident in our growth trajectory and committed to creating sustainable long-term shareholder value.” Q2FY27 Key metrics Revenue EBITDA EBITDA Margin PAT ₹ 940 cr ₹ 214 cr 22.8% ₹ 144 cr Page 5 +30.5% +48.3% +274 bps +44.8% Q2FY26 ₹ 720cr Q2FY26 ₹ 144 cr Q2FY26 20.1% Q2FY26 ₹ 99 cr www.marksanspharma.com Page 5 Financial Highlights H1FY27 – YoY Performance H1FY27 H1FY26 YoY Growth H1 YoY Performance Revenue grew 32.9% YoY, led by our core markets. UK & Europe contributed ₹312 cr, or 71% of the ₹441 cr Revenue ₹ 1,781.0 ₹ 1,340.4 32.9% increase, driven by new launches in the UK and ~₹84 cr cr cr from QliniQ. The US and ANZ added ₹83 cr and ₹70 cr respectively. Excluding QliniQ, our organic revenue remained strong at ~27% YoY. Gross profit rose ₹277 cr, up 36.0%, ahead of 32.9% Gross Profit ₹ 1,047.4 cr ₹ 770.0 cr 36.0% revenue growth, with gross margin expanding 137 bps Gross Margin 58.8% 57.4% to 58.8%. The expansion was supported by lower-cost inventory consumed during the period, particularly in Q1, and favorable currency gains and product mix. EBITDA margin expanded 574 bps to 24.0%, with 137 EBITDA ₹ 427.3 cr ₹ 244.6 cr 74.7% bps from gross margin and the balance from operating EBITDA Margin 24.0% 18.2% leverage, as costs below gross profit grew 18.0% against 32.9% revenue growth. Net Profit ₹ 302.9 cr ₹ 157.3 cr PAT rose ₹146 cr to ₹302.9 cr, up 92.5%, driven by 92.5% Net Margin 16.6% 11.5% EBITDA growth of ₹183 cr and higher other income. www.marksanspharma.com Note: Net Income Margin = Net profit / Total Income (Revenue from operations + Other Income) Page 6 Financial & Other Highlights – H1FY27 US & North America UK & Europe Australia & New Zealand Rest of World Revenue by geography ₹798 cr ₹761 cr ₹188 cr ₹34 cr +69.4% YoY +11.7% YoY +59.0% YoY -41.4% YoY Operating cash flow (H1FY27) EBITDA-to-cash conversion Free cash flow (H1FY27) Strong cash generation ₹322 cr 75% ₹275 cr 4.3x H1FY26 vs 31% in H1FY26 after ₹46 cr capex Cash balance Net cash added in H1FY27 Working capital cycle (H1FY27) Balance sheet strength to fund ₹1,124 cr +₹135 cr ~128 days growth net cash ₹1,095 cr after ₹95 cr M&A, ₹41 cr dividend from ~138 days in FY26 ROCE (TTM) ROE (TTM) Improving returns 24.7% 18.6% vs 18.7% a year ago vs 13.6% a year ago Europe front-end being established Strategic progress in H1 QliniQ contributed ~₹84 cr in H1FY27; ABCnow GmbH acquisition completed; R&D at ₹47.1 cr, 2.6% of revenue www.marksanspharma.com ROCE (TTM) = EBIT for the 12 months to 30 September ÷ capital employed (tangible net worth + total debt + deferred tax liabilities). ROE (TTM) = PAT for the 12 months to 30 September ÷ average of opening (30-Sep prior year) and closing equity. Page 7 Financial Highlights Q2FY27 – YoY Performance Q2FY27 Q2FY26 YoY Growth YoY Performance Revenue grew 30.5% YoY, with UK & Europe contributing Revenue ₹ 940.2 cr ₹ 720.4 cr 30.5% ₹159 cr, or 72% of the ₹220 cr increase, including ~₹40 cr from QliniQ. ANZ and the US contributed ₹39 cr and ₹34 cr respectively. Excluding QliniQ, our organic revenue remained strong at ~25% YoY. Gross profit rose ₹138 cr, up 33.6%, ahead of 30.5% Gross Profit ₹ 550.1 cr ₹ 411.8 cr 33.6% revenue growth, with gross margin expanding 135 bps Gross Margin 58.5% 57.2% to 58.5%. EBITDA margin expanded 274 bps to 22.8%: 135 bps EBITDA ₹ 214.3 cr ₹ 144.5 cr from gross margin and 139 bps from operating 48.3% EBITDA Margin 22.8% 20.1% leverage, as costs below gross profit grew 25.6% against 30.5% revenue growth. Net Profit ₹ 143.5 cr ₹ 99.1 cr PAT rose ₹44 cr to ₹143.5 cr, driven by EBITDA growth. 44.8% Net Margin 15.0% 13.4% www.marksanspharma.com Note: Net Income Margin = Net profit / Total Income (Revenue from operations + Other Income) Page 8 Financial Highlights Q2FY27 – QoQ Performance Q2FY27 Q1FY27 QoQ Growth QoQ Performance Revenue grew 11.8% QoQ to a record ₹940 cr, with Revenue ₹ 94 [Showing first 8,000 characters — download PDF for full document]